Nanaomycin A

Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells[1]. Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM[2].

Product Specifications

CAS Number

[52934-83-5]

UNSPSC

12352005

Hazard Statement

H301, H310

Target

Antibiotic; DNA Methyltransferase; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/nanaomycin-a.html

Purity

98.18

Solubility

10 mM in DMSO

Smiles

O=C(O)C[C@H]1CC(C(C2=C3C(O)=CC=C2)=O)=C(C3=O)[C@H](C)O1

Molecular Formula

C16H14O6

Molecular Weight

302.28

Precautions

H301, H310

References & Citations

[1]Kuck D, et al.Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells.Mol Cancer Ther. 2010 Nov;9 (11) :3015-23.|[2]Tanaka Y, et al.Heme-dependent radical generation: possible involvement in antimalarial action of non-peroxide microbial metabolites, nanaomycin A and radicicol.J Antibiot (Tokyo) . 1999 Oct;52 (10) :880-8.